MedTrace Logo

An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis

NCT00454584 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 903

Last updated 2012-11-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the efficacy and safety of CNTO 1275 to etanercept in patients with moderate to severe plaque psoriasis.

Conditions

Interventions

DRUG

CNTO 1275 45 mg

Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous

DRUG

CNTO 1275 90 mg

Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous

DRUG

Etanercept 50 mg

Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous

Sponsors & Collaborators

  • Centocor, Inc.

    lead INDUSTRY

Principal Investigators

  • Centocor, Inc. Clinical Trial · Centocor, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-01-31
Completion
2009-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00454584 on ClinicalTrials.gov